Loading...
Market
Revenue from BMS-Cellares CAR-T deal by 2026
5
Resolution / Starting Odds
Less than $200M • 25%
$200M to $400M • 25%
$400M to $600M • 25%
More than $600M • 25%
Financial disclosures and earnings reports from Bristol Myers Squibb and Cellares.
Story
Bristol Myers, Cellares Ink $380M Deal to Boost CAR-T Therapy Production
Apr 22, 2024, 01:01 PM
Bristol Myers Squibb has signed a significant $380 million agreement with Cellares to enhance the production and supply of CAR-T cell therapies. This partnership aims to extend the reach of these therapies to more patients across the United States, European Union, and Japan. The deal involves Cellares acting as a contract manufacturer to help meet the growing demand for these innovative treatments.
View original story
Similar markets
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
Under $200 million • 25%
Between $200 million and $500 million • 25%
Between $500 million and $800 million • 25%
Over $800 million • 25%
Increase in sales • 33%
Decrease in sales • 33%
No significant change • 34%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
Above $1.5 billion • 25%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Above $2 billion • 25%
Less than $10 million • 33%
$10 million to $20 million • 33%
More than $20 million • 33%
$0-100 million • 25%
$101-500 million • 25%
$501 million - $1 billion • 25%
Over $1 billion • 25%
Revenue from Imdelltra exceeds $1 billion • 25%
Revenue from Imdelltra is $500 million to $1 billion • 25%
Revenue from Imdelltra is $100 million to $500 million • 25%
Revenue from Imdelltra is less than $100 million • 25%
Less than $500 million • 33%
$500 million to $1 billion • 33%
Greater than $1 billion • 34%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Less than 500 million USD • 25%
500 million - 1 billion USD • 25%
1 billion - 2 billion USD • 25%
More than 2 billion USD • 25%
Outperform • 33%
Underperform • 33%
Match • 33%